Patient-Derived Organoids for Precision Cancer Immunotherapy

Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human ex vivo tumor assays that allow pretreatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells, but also the tumor microenvironment, including immune cells. Here, we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immunotherapy.

Automated summary

Cancer immunotherapy has transformed tumor treatment, but there is a lack of efficient testing platforms for pretreatment evaluation of therapies and understanding the tumor microenvironment. Patient-derived tumor organoid cultures and complex immune-organoid cultures offer potential for preclinical testing platforms in precision cancer immunotherapy.